IDE397

IDEAYA Biosciences · Phase 1 active Small molecule

At a glance

Generic name	IDE397
Sponsor	IDEAYA Biosciences
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors (PHASE1)
A Phase 1/2 Study of AMG 193 in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors (PHASE1, PHASE2)
Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

IDE397 CI brief — competitive landscape report
IDE397 updates RSS · CI watch RSS
IDEAYA Biosciences portfolio CI